Jonathan Chernoff, MD, PhD

Jon Chernoff, MD, PhD

Research Program

As Chief Scientific Officer, Dr. Chernoff coordinates and charts the future course of research at Fox Chase.

Chernoff joined the staff in 1991 as an associate member and was promoted to member with tenure in 1996. In 2002 he was promoted to be a senior member in Fox Chase Cancer Center's Basic Science division, the equivalent of a full professor in a university.

A molecular oncologist as well as a board-certified medical oncologist, Chernoff has a special interest in factors that control cell growth and movement, including oncogenes and anticancer or tumor-suppressor genes, and has made fundamental contributions in this research.

Chernoff earned his MD and his PhD in biochemistry in 1984 at Mount Sinai School of Medicine in New York City. He completed his residency in internal medicine at the University Health Center of Pittsburgh and a clinical fellowship in medical oncology at Johns Hopkins Oncology Center. He then held a postdoctoral fellowship in cellular and developmental biology at Harvard University before coming to Fox Chase.

In recognition of his national reputation in molecular oncology and biochemistry, Chernoff also holds the Stanley P. Reimann Chair in Oncology.

p21-activated kinases (Paks): cancer relevant pathways
Use of protein microarray to discovery new Pak targets
PTP1B is required for ErbB2-mediated transformation of MCF-10A cells
Education and Training

Educational Background

  • PhD, Biochemistry, Mt. Sinai School of Medcine, New York, NY, 1984
  • MD, Biochemistry, Mt. Sinai School of Medcine, New York, NY, 1984
  • BA, Molecular Biophysics and Biochemistry, Yale College, New Haven, CT, 1978

Honors & Awards

  • Faculty of 1000 (2007-present)
  • Stanley P. Reimann Chair in Oncology research (2008-present)
  • Fellow, American Association for the Advancement of Science (AAAS) (2017)
  • AACR, Educational Session Leader (2014)
  • Pennsylvania Drug Discovery Institute, Drug Discovery Award (2013)
  • Senior Fellow, American Asthma Assn (2008-2011)
  • Chair: NF2 Preclinical Consortium (2011-2012)
  • American Cancer Society, Southeast PA division, Scientific Research Award (2010)
  • Vice-Chair, FASEB “Small GTPases” (2008)
  • Chair, GRC “Mechanisms of Cell Signaling (2007)
  • Dozor Lecturer, Ben-Gurion University, Israel (2007)
  • Leukemia Society of America Scholar Award, (1997-2002)
  • ACS Research Scholar (1993-1998)
  • W.W. Smith Charitable Trust Fellowship 1993-1996
  • Pfizer Traveling Fellow (1996)
  • B.S. cum laude, Yale University (1978)
Research Profile

Research Program

Research Interests

  • Proliferative signal transduction
  • Regulation of neoplastic growth by protein kinases and phosphatases
  • Regulation and role of p21-activated kinases in cancer
  • Hippo tumor suppressor pathway

Lab Overview

The process of neoplastic transformation can be conceptually divided into two components. The first of these, proliferative transformation, refers to the ability of transformed cells to bypass growth suppression signals, suriviving and dividing when normal cells would not. The second, morphologic transformation, refers to loss of normal cytoskeletal architecture, often accompanied by decreased adhesion and acquisition of the ability to invade surrounding tissues. These two fundamental properties are intimately linked to one another, although experimentally they can be dissected apart through the use of gain-of-function and loss-of-function manupulation of signaling molecules. The overall focus this research is in uncovering the roles of protein phosphorylation in governing these two fundamental aspects of cancer biology. 

Lab Staff

Hoi Yee (Betty) Chow, PhD

Visiting Scientist

Room: W451

Cristina Uribe-Alvarez, PhD

Postdoctoral Associate

Room: W450

Gleb Abalakov, MD

Scientific Associate

Room: W450

Dorothy Benton, BS

Graduate Student, Drexel University College of Medicine

Room: W450

Konstantin Budagyan, BS

Graduate Student, Drexel University College of Medicine

Room: W451

Alexa Cannon, BS

Graduate Student, Drexel University College of Medicine

Room: W450

Sofiia Karchugina

Graduate Student, Pirogov Russian National Research Medical University

Room: W451

Anne Carson

Senior Administrative Assistant to Jonathan Chernoff, MD, PhD, Chief Scientific Officer

Room: W455

Selected Publications

Binder P., Wang S., Radu M., Zin M., Collins L., Khan S., Li Y., Sekeres K., Humphreys N., Swanton E., Reid A., Pu F., Oceandy D., Guan K., Hille S.S., Frey N., Muller O.J., Cartwright E.J., Chernoff J., Liu W., Wang X., Pak2 as a novel therapeutic target for cardioprotective endoplasmic reticulum stress response. Circ Res. 124(5): 696-711, 2019.PMC6407830. 15.862

Chernoff J., How much is my paper worth? Mol Biol Cell. 30(23): 2878-2879, 2019. PMC6822591. 3.905

Kurimchak A.M., Shelton C., Herrera-Montavez C., Duncan K.E., Chernoff J., Duncan J.S., Intrinsic resistance to mek inhibition through bet protein mediated kinome reprogramming in nf1-deficient ovarian cancer. Mol Cancer Res. 17(8): 1721-1734, 2019. PMC6679760. 4.484

Lu H., Liu S., Zhang G., Wu B., Zhu Y., Frederick D.T., Hu Y., Zhong W., Randell S., Sadek N., Zhang W., Chen G., Cheng C., Zeng J., Wu L.W., Zhang J., Liu X., Xu W., Krepler C., Sproesser K., Xiao M., Miao B., Liu J., Song C.D., Liu J.Y., Karakousis G.C., Schuchter L.M., Lu Y., Mills G., Cong Y., Chernoff J., Guo J., Boland G.M., Sullivan R.J., Wei Z., Field J., Amaravadi R.K., Flaherty K.T., Herlyn M., Xu X. ,Guo W., Author correction: Pak signalling drives acquired drug resistance to mapk inhibitors in braf-mutant melanomas. Nature. 565(7738): E4, 2019. 43.070

Sannai M., Doneddu V., Giri V., Seeholzer S., Nicolas E., Yip S.C., Bassi M.R., Mancuso P., Cortellino S., Cigliano A., Lurie R., Ding H., Chernoff J., Sobol R.W., Yen T.J., Bagella L., Bellacosa A., Modification of the base excision repair enzyme mbd4 by the small ubiquitin-like molecule sumo1. DNA Repair. 82: 102687, 2019.PMC6785017. 3.711

Araiza-Olivera D. ,Chernoff J., Hras helps hippo heterodimerize to evade tumor suppression. Small GTPases. 9(4): 327-331, 2018. PMC5997136. 

Chow HY, Dong B, Valencia CA, Zeng CT, Koch JN, Prudnikova TY, Chernoff J. Group I Paks are essential for epithelial- mesenchymal transition in an Apc-driven model of colorectal cancer. Nature communications, 9(1):3473, 2018. PMC6110733

Karchugina S., Chernoff J., Detection of heterodimerization of protein isoforms using an in situ proximity ligation assay. J Vis Exp, (140)2018. PMC6235567. 1.108

Kim S.M., Nguyen T.T., Ravi A., Kubiniok P., Finicle B.T., Jayashankar V., Malacrida L., Hou J., Robertson J., Gao D., Chernoff J., Digman M.A., Potma E.O., Tromberg B.J., Thibault P.,Edinger A.L., Pten deficiency and ampk activation promote nutrient scavenging and anabolism in prostate cancer cells. Cancer Discov. 8(7): 866-883, 2018. PMC6030497. 26.370

Stepanova D.S., Braun L., Chernoff J., A new concept in nf2 pharmacotherapy: Targeting fatty acid synthesis. Oncoscience. 5(5-6): 126-127, 2018. PMC6049319.

Prudnikova T.Y., Chernoff J., The group i pak inhibitor frax-1036 sensitizes 11q13-amplified ovarian cancer cells to the cytotoxic effects of rottlerin. Small GTPases. 8(4): 193-198, 2017. PMC5680705. 2.048

Semenova G., Chernoff J., Targeting pak1. Biochem Soc Trans. 45(1): 79-88, 2017. PMC5973817. 4.291

Semenova G., Stepanova D., Deyev S.M., Chernoff J., Medium throughput biochemical compound screening identifies novel agents for pharmacotherapy of neurofibromatosis type i. Biochimie. 135: 1-5, 2017. PMC5405558. 3.362

Araiza-Olivera D, Feng Y, Semenova G, Prudnikova TY, Rhodes J, Chernoff J. Suppression of RAC1-driven malignant melanoma by group A PAK inhibitors. Oncogene, 37(7):944-52, 2018. PMC5814328

Semenova G, Stepanova DS, Dubyk C, Handorf E, Deyev SM, Lazar AJ, Chernoff J. Targeting group I p21-activated kinases to control malignant peripheral nerve sheath tumor growth and metastasis. Oncogene, 36(38):5421-31, 2017. PMC5608634 ... Expand

Additional Publications


Connect with Fox Chase